Director dealings

RNS Number : 1064M
Intelligent Ultrasound Group PLC
06 May 2020
 

Intelligent Ultrasound Group plc

("Intelligent Ultrasound" or the "Company")

 

Director Dealings

 

Intelligent Ultrasound (AIM: MED), the intelligent ultrasound software and simulation company, announces that further to the Company's announcements on 17 April 2020 and 4 May 2020, certain Directors have, following Admission today, acquired a total of 409,523 Ordinary Shares in the Company via the Placing, as detailed below:

 

Name

Title 

Number of Existing Ordinary Shares#

Number of Placing Shares subscribed for#

Value of Placing Shares subscribed for#

Resulting shareholding following subscription #

Percentage of enlarged share capital following subscription#

Stuart Gall

Chief Executive Officer 

828,236

95,238

£10,000

923,474

0.34%

Helen Jones

Chief Financial Officer 

0

95,238

£10,000

95,238

0.04%

Nicholas Sleep

Chief Technology Officer

326,471

95,238

£10,000

421,709

0.16%

Ian Whittaker

Chief Operating Officer

374,982

76,190

£8,000

451,172

0.17%

Nick Avis

Non-Executive Director

225,000

47,619

£5,000

272,619

0.10%

 

# The number of Ordinary Shares presented in this table as being held or subscribed for by Directors refers to the number of Ordinary Shares held or subscribed for by them either personally or through a nominee.

 

Unless otherwise defined herein, capitalised terms used in this announcement shall have the same meanings as defined in the circular sent to shareholders of the Company on 17 April 2020.

The Company makes the following disclosures in accordance with article 19(3) of the Market Abuse Regulation:

1

Details of the person discharging managerial responsibilities / person closely associated

a)

 

Name

 

 

1.  Stuart Gall

2.  Helen Jones

3.  Nicholas Sleep

4.  Ian Whittaker

5.  Nick Avis

2

Reason for the notification

a)

 

Position/status

 

 

1.  Chief Executive Officer 

2.  Chief Finance Officer 

3.  Chief Technology Officer

4.  Chief Operating Officer

5.  Non-Executive Director

b)

Initial notification /Amendment

Initial

3

 

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Intelligent Ultrasound Group plc

b)

LEI

213800K4ZVWL4ZYQAZ70

4

 

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

 

Description of the financial instrument, type of instrument

 

Identification code

Ordinary Shares of 1 pence each

 

ISIN: GB00BN791Q39

b)

Nature of the transaction

Purchase of Ordinary Shares

c)

 

Price(s) and volume(s)

 

 

 

Price(s)

Volume(s)

1.  10.5  pence

2.  10.5  pence

3.  10.5  pence

4.  10.5  pence

5.  10.5  pence

 

1.  95,238

2.  95,238

3.  95,238

4.  76,190

5.  47,619

 

d)

Aggregated information

- Aggregated volume

- Price

 

N/A - single transaction

e)

Date of the transaction

6 May 2020

f)

Place of the transaction

London Stock Exchange, XLON

 

Enquiries:

Intelligent Ultrasound Group plc

www.intelligentultrasound.com

Stuart Gall, CEO
Helen Jones, CFO

Tel: +44 (0)29 2075 6534



Cenkos Securities plc

Tel:  +44 (0)20 7397 8900

Giles Balleny (Nominated Adviser)


Michael Johnson/Julian Morse (Corporate Broking)




Walbrook PR

Tel: +44 (0)20 7933 8780 or  intelligentultrasound@walbrookpr.com

Anna Dunphy/Paul McManus

Mob: +44 (0)7876 741 001/Mob: +44 (0)7980 541 893

 

About Intelligent Ultrasound Group

Intelligent Ultrasound (AIM: MED) develops artificial intelligence-based clinical image analysis software tools for the diagnostic medical ultrasound market and hi-fidelity virtual reality simulators for the ultrasound training market.


Based in Cardiff and Oxford in the UK, Atlanta in the US and with representation in Beijing in Asia, the Group operates two divisions:


Clinical AI Division

Focusses on developing deep learning-based algorithms to make ultrasound machines smarter and more accessible. Products in development include ScanNav which uses machine-learning based algorithms to automatically identify and grade ultrasound images to provide scan assessment and audit of protocol-based ultrasound scanning; and  AnatomyGuide, which aims to simplify ultrasound-guided needling by providing the user with real-time AI-based needle guidance software for a range of medical procedures.

 

Simulation Division

Focusses on hi-fidelity ultrasound education and training through simulation.  Its three main products are the ScanTrainer OBGYN training simulator, the HeartWorks echocardiography training simulator and the BodyWorks Eve Point of Care and Emergency Medicine training simulator. To date over 800 simulators have been sold to almost 500 medical institutions around the world.

 

www.intelligentultrasound.com

 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
DSHFZGGKRVZGGZG
UK 100

Latest directors dealings